Compliance Considerations in Pharmaceutical Product Development Compliance Considerations in Pharmaceutical Product Development John C. (Jack) Garvey,
FDA Compliance Actions Against IRBs and Clinical Investigators Paul W. Goebel, Jr., CIP Vice President [email protected] Chesapeake Research Review,
Developing and Presenting Posters This educational presentation was reviewed and endorsed by IACRNs education committee. August 2011.
Understanding Our HRPP and Your Role in the Accreditation Process.
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events S. Percy Ivy, MD Associate Chief, Senior Investigator Investigational.
Ann Johnson IRB Administrator, IRB Member. Objectives 1. Identify the components necessary for management and oversight of tissue repositories used for.
NIH RESEARCH CONTRACTS Rosemary M. Hamill Procurement Analyst Division of Acquisition Policy and Evaluation Office of Acquisition Management and Policy.
NIH RESEARCH CONTRACTS Rosemary M. Hamill Procurement Analyst Office of Acquisitions National Cancer Institute NIH/DHHS.
Biosafety in Biomedical Laboratories June 2, 2009 Marshall University Summer Students/Recent Hires Please complete the sign in sheet.
Centre for Investigational New Product National Pharmaceutical Control Bureau, MOH.
R
How To Optimize Your EDC Solution For Risk Based Monitoring
